Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341742 | 0.90 | MAPK1 (0.46) | MAPTGSK3BABL1F10ACKR3 | |
| SCHEMBL3362758 | 0.89 | ABL1 (0.52) | MAPTGSK3BABL1ADORA3ADORA2A | |
| SCHEMBL3347092 | 0.88 | NPC1 (0.47) | MAPTDGAT1KMT2ANPC1RAB9A | |
| SCHEMBL10192549 | 0.81 | HTT (0.50) | MAPTABL1TSHRKMT2ANPC1 | |
| SCHEMBL3334156 | 0.79 | EPHX1 (0.46) | KMT2ANPC1RAB9A | |
| SCHEMBL3327579 | 0.78 | PTPN2 (0.51) | ADORA3ADORA2AADORA1TSHRNPC1 | |
| SCHEMBL10192285 | 0.76 | NPY5R (0.49) | — | |
| SCHEMBL3343347 | 0.74 | JAK2 (0.48) | ABL1TSHR | |
| SCHEMBL14108403 | 0.74 | MLLT1 (0.47) | TSHRKMT2ANPC1RAB9A | |
| SCHEMBL3320027 | 0.74 | ABL1 (0.46) | MAPTGSK3BABL1F10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653125-B2 | Cyclohexane derivative having NPY Y5 receptor antagonism | SHIONOGI CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | MAPT 4378/4885GSK3B 3052/4885ABL1 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.